Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Lung Cancer ; 194: 107866, 2024 Jun 29.
Article in English | MEDLINE | ID: mdl-38972083

ABSTRACT

BACKGROUND: First-line standard-of-care for unresectable, pleural mesothelioma (PM) changed with the phase 3 CheckMate 743 study results, showing that nivolumab plus ipilimumab (Nivo + Ipi) significantly extended overall survival (OS) versus platinum + pemetrexed chemotherapy for PM (median OS 18.1 versus 14.1 months; hazard ratio: 0.74; p = 0.002). Efficacy and safety data in real-world (rw) settings are needed to confirm these results. METHODS: This French multicenter, retrospective cohort study was undertaken to assess the outcomes of treatment-naïve PM patients given Nivo + Ipi via an early-access program (EAP). The primary objective was investigator-assessed real world -progression-free survival (PFS). The secondary objectives were the combination's -overall survival (OS) and safety. RESULTS: From 1 April 2021 to 15 Feb 2022, the analysis included 201 of the 305 EAP-enrolled patients treated in 63 centers (79.6 % men; median age: 75 years; 91.8 % Eastern Cooperative Oncology Group performance status (ECOG-PS) 0/1; 74.5 % epithelioid histology). With median (95 % CI) follow-up for all patients of 18.4 (17.7-19.2) months, -PFS and OS were 6.3 (5.3-7.5) and 18.9 (17.6-not reached (NR)) months, with 1-year OS at 66.4 % (60.1-73.3 %). Median OS and 1-year survival rates were 21.0 (18.7-NR) and 70.8 % (63.9 %-780.6 %), and 14.1 (10.9-21.0) months and 54.9 % (42.8 %-70.4 %) for epithelioid and non-epithelioid PM subgroups, respectively. PFS was equal between the two subgroups. Grade 3-4 adverse events occurred in 23.3 % of patients and three deaths were treatment-related. CONCLUSIONS: For this unselected PM population, efficacy and safety outcomes compared favorably with CheckMate 743 trial results.

2.
EClinicalMedicine ; 28: 100566, 2020 Nov.
Article in English | MEDLINE | ID: mdl-33205032

ABSTRACT

BACKGROUND: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improved pathological complete response (pCR) rates (43.8% vs 24.0%). We investigated long-term study outcomes. METHODS: Patients were treated in three groups. All patients initially received two cycles of standard neoadjuvant therapy with [¹8F]-FDG PET conducted before each cycle. Those with ≥70% change in the maximum standardised uptake value (∆SUVmax) received four further cycles of standard neoadjuvant therapy (PET responders). PET-predicted poor-responders (∆SUVmax <70%) were randomised (2:1) to neoadjuvant therapy with (Group A) or without (Group B) bevacizumab for cycles 3-6. All patients received one further cycle of trastuzumab before surgery plus adjuvant trastuzumab (11 cycles). FINDINGS: 142 patients were randomized and treated (PET responders, n = 69; Group A, n = 48; Group B, n = 25). 5-year disease-free survival rates were 90.5% (95% CI: 80.0-95.6%) in PET responders, 90.2% (95% CI: 75.9-96.2%) in Group A, and 76.0% (95% CI: 54.2-88.4%) in Group B. However, no difference was observed between randomised arms in a sensitivity analysis. During adjuvant therapy, the incidence of Grade ≥3 (Group A: 25.6%; Group B 12.5%) and serious adverse events (Group A: 18.6%; Group B 12.5%) was higher in Group A vs Group B, but with no apparent effect on cardiac events. INTERPRETATION: In patients with HER2-positive breast cancer, an intervention based on early PET assessment and improvement of pCR does not modify disease-free survival. FUNDING: Roche France.

3.
Lancet Oncol ; 15(13): 1493-1502, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25456368

ABSTRACT

BACKGROUND: An effective and well tolerated treatment is needed for patients with early HER2-positive breast cancer who do not achieve a pathological complete response after neoadjuvant therapy. The AVATAXHER trial aimed to predict pathological complete response early with the use of PET and to investigate whether the addition of bevacizumab could improve the proportion of patients achieving a pathological complete response in patients unlikely to respond to treatment. METHODS: AVATAXHER was a randomised, open-label, non-comparative, multicentre phase 2 study that enrolled women (≥18 years of age) with early-stage HER2-positive breast cancer from 26 oncology centres in France. Patients initially received two cycles of neoadjuvant docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (8 mg/kg intravenously every 3 weeks then 6 mg/kg intravenously every 3 weeks for the second course). Before the first and second cycles, [(18)F]-fluorodeoxyglucose (FDG) PET was done and the change in standardised uptake value was used to predict pathological complete response in each patient. Patients who were predicted to be responders on PET continued to receive standard therapy. Predicted non-responders were randomly assigned (2:1) to receive four cycles of docetaxel (100 mg/m(2) intravenously every 3 weeks) and trastuzumab (6 mg/kg intravenously every 3 weeks) plus bevacizumab (15 mg/kg intravenously every 3 weeks; group A) or continue on docetaxel plus trastuzumab alone (group B). Randomisation was open label and was done by an adaptive minimisation method. Although investigators and patients were aware of group assignment, the anatomo-pathologist in charge of centralised review of surgical samples and lymph nodes was masked to treatment assignment. The primary endpoint was centrally assessed pathological complete response according to the Chevallier classification. Efficacy analyses were done in the intention-to-treat population. Safety analyses in this Article were done on all patients who received at least one dose of treatment starting from cycle 3. Survival outcomes are not yet mature. This study is registered with ClinicalTrials.gov (NCT01142778) and EUDRACT (2009-013410-26). FINDINGS: Between May 19, 2010, and Oct 1, 2012, 152 patients were recruited for the study. Ten patients were subsequently excluded, leaving 142 patients in the intention-to-treat population. Of these 142 patients, 69 were predicted by [(18)F]-FDG PET to be treatment responders after two cycles of treatment. The 73 predicted non-responders were randomly assigned to group A (n=48) and group B (n=25). Pathological complete responses were noted in 37 (53·6%, 95% CI 41·2-65·7) of the PET responders, 21 (43·8%, 29·5-58·8) of those in group A, and six (24·0%, 9·4-45·1) of those in group B. Incidences of grade 3-4 adverse events were similar in all three groups. The most common grade 3-4 adverse events were neutropenia (four in PET responders, five in group A, and three in group B), febrile neutropenia (one, three, and one, respectively), and myalgia (four, none, and one, respectively). Overall, 24 serious adverse events were reported in 15 patients (PET responders: nine events in four [6%] of 67 patients; group A: 14 events in ten [21%] of 47 patients; group B: one event in one [4%] of 25 patients). No deaths occurred during the study. INTERPRETATION: In patients with HER2-positive breast cancer, early PET assessment can help to identify non-responders to neoadjuvant docetaxel plus trastuzumab therapy. In these patients, the addition of bevacizumab can increase the proportion of patients achieving a pathological complete response. This potential new role for PET and the activity of bevacizumab in this setting need to be confirmed in larger phase 3 trials. FUNDING: Roche France.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/diagnostic imaging , Carcinoma, Ductal, Breast/diagnostic imaging , Fluorodeoxyglucose F18 , Neoadjuvant Therapy , Positron-Emission Tomography , Receptor, ErbB-2/metabolism , Adult , Antibodies, Monoclonal, Humanized/administration & dosage , Bevacizumab , Breast Neoplasms/drug therapy , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/secondary , Chemotherapy, Adjuvant , Combined Modality Therapy , Docetaxel , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Middle Aged , Neoplasm Grading , Neoplasm Staging , Prognosis , Radiopharmaceuticals , Survival Rate , Taxoids/administration & dosage , Trastuzumab
4.
Int J Radiat Oncol Biol Phys ; 77(1): 31-7, 2010 May 01.
Article in English | MEDLINE | ID: mdl-19864077

ABSTRACT

PURPOSE: To determine the impact of stereotactic radiotherapy on the quality of life of patients with inoperable early-stage non-small-cell lung cancer (NSCLC). Overall survival, local tumor control, and toxicity were also evaluated in this prospective study. METHODS AND MATERIALS: From January 2006 to February 2008, quality of life, overall survival, and local tumor control were assessed in 39 patients with pathologically confirmed T1 to 2N0M0 NSCLC. These patients were treated with stereotactic radiotherapy. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30 and the QLQ LC13 lung cancer-specific questionnaire were used to investigate changes in quality of life. Assessments were done before treatment, at 3 weeks, and at 2, 4, 6, 9, and 12 months after treatment, until death or progressive disease. Toxicity was evaluated using common terminology criteria for adverse events version 3.0. RESULTS: Emotional functioning improved significantly after treatment. Other function scores and QLQ C30 and QLQ LC13 lung symptoms (such as dyspnea and coughing) showed no significant changes. The overall 2-year survival rate was 62%. After a median follow-up of 17 months, 1 patient had a local recurrence (3%). No grade 4 or 5 treatment-related toxicity occurred. Grade 3 toxicity consisted of thoracic pain, which occurred in 1 patient within 4 months of treatment, while it occurred thereafter in 2 patients. CONCLUSIONS: Quality of life was maintained, and emotional functioning improved significantly after stereotactic radiotherapy for stage I NSCLC, while survival was acceptable, local tumor control was high, and toxicity was low.


Subject(s)
Carcinoma, Non-Small-Cell Lung/surgery , Lung Neoplasms/surgery , Quality of Life , Radiosurgery/methods , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/psychology , Cough/surgery , Dyspnea/surgery , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lung Neoplasms/psychology , Middle Aged , Prospective Studies , Radiosurgery/adverse effects , Radiosurgery/mortality , Surveys and Questionnaires , Survival Rate
5.
Int J Radiat Oncol Biol Phys ; 74(1): 297-303, 2009 May 01.
Article in English | MEDLINE | ID: mdl-19362249

ABSTRACT

PURPOSE: To quantify the clinical accuracy of the respiratory motion tracking system of the CyberKnife treatment device. METHODS AND MATERIALS: Data in log files of 44 lung cancer patients treated with tumor tracking were analyzed. Errors in the correlation model, which relates the internal target motion with the external breathing motion, were quantified. The correlation model error was compared with the geometric error obtained when no respiratory tracking was used. Errors in the prediction method were calculated by subtracting the predicted position from the actual measured position after 192.5 ms (the time lag to prediction in our current system). The prediction error was also measured for a time lag of 115 ms and a new prediction method. RESULTS: The mean correlation model errors were less than 0.3 mm. Standard deviations describing intrafraction variations around the whole-fraction mean error were 0.2 to 1.9 mm for cranio-caudal, 0.1 to 1.9 mm for left-right, and 0.2 to 2.5 mm for anterior-posterior directions. Without the use of respiratory tracking, these variations would have been 0.2 to 8.1 mm, 0.2 to 5.5 mm, and 0.2 to 4.4 mm. The overall mean prediction error was small (0.0 +/- 0.0 mm) for all directions. The intrafraction standard deviation ranged from 0.0 to 2.9 mm for a time delay of 192.5 ms but was halved by using the new prediction method. CONCLUSIONS: Analyses of the log files of real clinical cases have shown that the geometric error caused by respiratory motion is substantially reduced by the application of respiratory motion tracking.


Subject(s)
Lung Neoplasms/surgery , Movement , Radiosurgery/instrumentation , Respiration , Robotics/instrumentation , Algorithms , Humans , Lung , Radiology Information Systems , Radiosurgery/standards , Reference Standards , Robotics/standards
6.
Radiother Oncol ; 91(3): 296-300, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19297048

ABSTRACT

PURPOSE: To report the clinical outcome of treatment using real-time tumor tracking for 70 patients with inoperable stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Seventy inoperable patients with peripherally located early-stage NSCLC were treated with 45 or 60 Gy in three fractions using CyberKnife. Pathology was available in 51% of patients. Thirty-nine patients had a T1-tumor and 31 had a T2-tumor. Markers were placed using the vascular, percutaneous intra-, or extra-pulmonary approach, depending on the risk of pneumothorax. RESULTS: The actuarial 2-year local control rate for patients treated with 60 Gy was 96%, compared to 78% for patients treated with a total dose of 45 Gy (p=0.197). All local recurrences (n=4) occurred in patients with T2-tumors. Overall survival for the whole group at two years was 62% and the cause specific survival was 85%. The median follow-up was 15 months. Grade 3 toxicity occurred in two patients (3%) after marker placement. Treatment-related late grade 3 toxicity occurred in 7 patients (10%). No grade > or = 4 toxicity occurred. CONCLUSION: Excellent local control of 96% at 1- and 2-years was achieved using 60 Gy in three fractions for NSCLC patients treated with the real-time tumor tracking. Toxicity was low.


Subject(s)
Carcinoma, Non-Small-Cell Lung/surgery , Lung Neoplasms/surgery , Radiosurgery/methods , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/pathology , Comorbidity , Dose Fractionation, Radiation , Female , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Proportional Hazards Models , Radiation Injuries/etiology , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Survival Rate , Tomography, X-Ray Computed , Treatment Outcome
7.
Med Phys ; 35(6): 2294-9, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18649461

ABSTRACT

Advances in image guidance and dose delivery techniques, and increased use of hypofractionation, have led to prolonged radiotherapy fraction duration. This is also the case with robotic radiosurgery, as extensive on-line image guidance procedures, many beams, and usually high fraction doses are used for tumor irradiation. At this institution, early stage non-small-cell lung cancer patients are treated with image guided tumor tracking for respiratory motion compensation. Approximately 130 circular beams and up to approximately 39 000 monitor units (MUs) are used for delivery of a total treatment dose of 60 Gy. The large number of MUs leads to long treatment times and the radiation leakage increases with the number of MUs. Generally, per patient, a single (small) cone is used. To substantially reduce the number of MUs, the authors have developed a new planning strategy for combined use of a small and a large cone. The large cone aims at dose delivery around the PTV center, while the small cone shapes the dose around the (irregular) PTV edges. The authors systematically investigated relationships between the number of MUs, the plan quality, the selected cone diameters, and the beam-direction setup. Plan quality was assessed with the conformity index, mean lung dose (MLD), V20 of the lungs, and by visual inspection. The reduction in MUs was determined by comparing two-cone plans with corresponding one-cone plans that yielded equal MLD, i.e., equal predicted lung toxicity. With the proposed two-cone approach, the required number of MUs reduced by on average 31% (range 4%-56%). The beam-on time per treatment fraction reduced by on average 8 min (range 1-15.2 min). All plans obeyed the clinically applied constraints and were considered clinically acceptable by an involved physician.


Subject(s)
Radiosurgery/instrumentation , Radiosurgery/methods , Radiotherapy Planning, Computer-Assisted/methods , Robotics , Humans , Lung Neoplasms/radiotherapy , Lung Neoplasms/surgery , Physicians , Radiotherapy Dosage
8.
Eur Radiol ; 18(8): 1569-76, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18389249

ABSTRACT

To evaluate the use of endovascular coils as markers for respiratory motion correction during high-dose stereotactic radiotherapy with the CyberKnife, an image-guided linear accelerator mounted on a robotic arm. Endovascular platinum embolisation coils were used to mark intrapulmonary lesions. The coils were placed in subsegmental pulmonary artery branches in close proximity to the target tumour. This procedure was attempted in 25 patients who were considered unsuitable candidates for standard transthoracic percutaneous insertion. Vascular coils (n = 87) were successfully inserted in 23 of 25 patients. Only minor complications were observed: haemoptysis during the procedure (one patient), development of pleural pain and fever on the day of procedure (one patient), and development of small infiltrative changes distal to the vascular coil (five patients). Fifty-seven coils (66% of total inserted number) could be used as tumour markers for delivery of biologically highly effective radiation doses with automated tracking during CyberKnife radiotherapy. Endovascular markers are safe and allow high-dose radiotherapy of lung tumours with CyberKnife, also in patients who are unsuitable candidates for standard transthoracic percutaneous marker insertion.


Subject(s)
Angiography/instrumentation , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/radiotherapy , Embolization, Therapeutic/instrumentation , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/radiotherapy , Radiography, Interventional/instrumentation , Radiosurgery/instrumentation , Adult , Aged , Aged, 80 and over , Angiography/methods , Computer Systems , Female , Humans , Image Enhancement/instrumentation , Image Enhancement/methods , Male , Middle Aged , Pilot Projects , Radiography, Interventional/methods , Radiosurgery/methods , Treatment Outcome
9.
Radiother Oncol ; 87(2): 268-73, 2008 May.
Article in English | MEDLINE | ID: mdl-18262672

ABSTRACT

PURPOSE: To determine adequate three-dimensional (3D) margins around the clinical target volume (CTV) of oropharyngeal cancers. METHODS AND MATERIALS: The CTV, bounded by implanted markers, was recorded under fluoroscopy in antero-posterior (AP) and lateral view. The peak-to-peak motion was measured in lateral, AP and cranio-caudal (CC) directions. RESULTS: During swallowing, the mean amplitude of motion measured was 9.4mm (0.9-18.5) and 4.1mm (0.6-11.4) in AP view in the CC and lateral direction, respectively; and 8.6mm (0.5-16.5) and 7.6mm (0.9-14.5) in lateral view in the CC and AP direction, respectively. In the non-swallowing period the motion was 1.5mm (0.3-3.2) and 1mm (0.4-3.6) in AP view in the CC and lateral direction, respectively; and 1.3mm (0.4-3.1) and 1.3mm (0.4-3.4) in lateral view in the CC and AP direction, respectively. This motion was believed to be due to breathing. CONCLUSION: If swallowing can be suppressed during CT acquisition, the contribution to the internal margin for this motion is negligible. Breathing related motion is also believed to be of limited clinical relevance in current practice. However, it might become of importance in future, with further reduction of margins.


Subject(s)
Carcinoma, Squamous Cell/surgery , Movement , Oropharyngeal Neoplasms/surgery , Radiosurgery/instrumentation , Carcinoma, Squamous Cell/pathology , Deglutition/physiology , Fluoroscopy , Humans , Oropharyngeal Neoplasms/pathology , Radiotherapy Dosage , Respiration
10.
Radiother Oncol ; 85(1): 64-73, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17714815

ABSTRACT

PURPOSE/OBJECTIVE: To assess the relationship between the radiation therapy (RT) dose received by the muscular components of the swallowing (sw) apparatus and - dysphagia related - quality of life (QoL) in oropharyngeal cancer. MATERIALS/METHODS: Between 2000 and 2005, 81 patients with SCC of the oropharynx were treated by 3DCRT or IMRT, with or without concomitant chemotherapy (CHT); 43 out of these 81 patients were boosted by brachytherapy (BT). Charts of 81 patients were reviewed with regard to late dysphagia complaints; 23% experienced severe dysphagia. Seventeen patients expired. Fifty-six out of 64 (88%) responded to quality of life (QoL) questionnaires; that is, the Performance Status Scales of List, EORTC H&N35, and the M.D. Anderson Dysphagia Inventory. The superior (scm), middle (mcm), and inferior constrictor muscle (icm), the cricopharyngeus muscle and the inlet of the esophagus, are considered of paramount importance for swallowing. The mean dose was calculated in the muscular structures. Univariate analysis and multivariate analysis were performed using the proportional odds model. RESULTS: Mean follow-up was 18 months (range 2-34) for IMRT, and 46 months for 3DCRT (range 2-72). At 3-years, a LRC of 84%, DFS of 78% and OS of 77% were observed. A significant correlation was observed between the mean dose in the scm and mcm, and severe dysphagia complaints (univariate analysis). A steep dose-effect relationship, with an increase of the probability of dysphagia of 19% with every additional 10 Gy, was established. In the multivariate analysis, BT (dose) was the only significant factor. CONCLUSION: A dose-effect relationship between dose and swallowing complaints was observed. One way to improve the QoL is to constrain the dose to be received by the swallowing muscles.


Subject(s)
Brachytherapy/adverse effects , Carcinoma, Squamous Cell/radiotherapy , Deglutition Disorders/etiology , Oropharyngeal Neoplasms/radiotherapy , Pharyngeal Muscles/radiation effects , Radiotherapy, Conformal/adverse effects , Radiotherapy, Intensity-Modulated/adverse effects , Adult , Aged , Carcinoma, Squamous Cell/psychology , Dose-Response Relationship, Radiation , Female , Humans , Male , Middle Aged , Oropharyngeal Neoplasms/psychology , Quality of Life , Radiotherapy Dosage
11.
Tumori ; 90(6): 618-21, 2004.
Article in English | MEDLINE | ID: mdl-15762367

ABSTRACT

We report a case of postirradiation sarcoma that arose in the right inguinal region 8 years after completion of external beam radiation therapy for a localized adenocarcinoma of the prostate. The patient was treated in 1995 with a "mixed-beams" technique (18 MV photons and 65 MeV fast neutrons). Eight years after the end of treatment, he presented with a radio-induced, high-grade spindle-cell sarcoma. Cytogenetic analysis was performed to confirm the diagnosis. Although the use of external beam radiation therapy for the treatment of prostate cancer has been common practice for decades, postirradiation sarcomas have been reported to be rare sequelae of irradiation and, to our knowledge, only a few of them were cytogenetically investigated.


Subject(s)
Adenocarcinoma/radiotherapy , Neoplasms, Radiation-Induced/etiology , Neoplasms, Second Primary/etiology , Prostatic Neoplasms/radiotherapy , Sarcoma/etiology , Aged , Humans , Male , Radiotherapy/adverse effects , Radiotherapy/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...